A Johnson & Johnson unit has filed for Swiss approval to sell ceftobiprole, marketed in partnership with developer Basilea Pharmaceutical, as a treatment for diabetic foot infections. The drug already is on the Swiss fast track for possible treatment of skin and soft-tissue infections, and it's under review by regulators in the U.S., Canada, and the E.U.
- see this announcement
- read the AFX report
Related Articles:
J&J makes big cuts at Alza and Scios. Report
&J restructures pharma unit, laying off workers. Report